AstraZeneca to take over Fusion Therapeutics Inc
Fusion Pharmaceuticals Inc‘s acquisition for US$2bn upfront marks a major step forward in AstraZeneca delivering on its ambition to transform cancer...
Finnish Enifer Oy secures €12m grant to scale up
The new factory will have a production capacity of around 3 million kilograms a year – equal to the amount of protein from 30,000 cows but with...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Roche opens €90m gene therapy development centre
Roche sees the €90m investment as a harbinger of the German government's "National Strategy for Gene and Cell Therapies", which has been...
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...